Operating Segments

9 Months Ended

12 Months Ended

Sep. 30, 2023

Dec. 31, 2022

Operating Segments

Operating Segments

Note 11. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended
	September 30,
	2023		2022
Revenues
Specialized BioTherapeutics	$	—	$	—
Public Health Solutions		130,440		166,140
Total	$	130,440	$	166,140
Income (loss) from Operations
Specialized BioTherapeutics	$	(705,753)	$	(1,856,553)
Public Health Solutions		(24,819)		(9,578)
Corporate		(1,048,484)		(1,215,113)
Total	$	(1,779,056)	$	(3,081,244)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	954	$	2,876
Public Health Solutions		159		479
Corporate		476		1,438
Total	$	1,589	$	4,793
Other (Expense) Income, Net
Specialized BioTherapeutics	$	1,683	$	(12,613)
Corporate		114,671		(215,146)
Total	$	116,354	$	(227,759)
Share-Based Compensation
Specialized BioTherapeutics	$	27,427	$	28,343
Public Health Solutions		994		1,054
Corporate		36,979		41,318
Total	$	65,400	$	70,715

	Nine Months Ended
	September 30,
	2023		2022
Revenues
Specialized BioTherapeutics	$	223,870	$	—
Public Health Solutions		370,677		582,843
Total	$	594,547	$	582,843
Income (loss) from Operations
Specialized BioTherapeutics	$	(2,227,430)	$	(5,396,630)
Public Health Solutions		(26,639)		(131,201)
Corporate		(3,306,000)		(5,141,095)
Total	$	(5,560,069)	$	(10,668,926)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	2,979	$	8,273
Public Health Solutions		496		1,379
Corporate		1,489		11,886
Total	$	4,964	$	21,538
Other (Expense) Income, Net
Specialized BioTherapeutics	$	17,696	$	110,975
Corporate		60,341		(641,768)
Total	$	78,037	$	(530,793)
Share-Based Compensation
Specialized BioTherapeutics	$	82,281	$	85,190
Public Health Solutions		2,982		3,162
Corporate		143,813		132,304
Total	$	229,076	$	220,656

	As of		As of
	September 30,		December 31,
	2023		2022
Identifiable Assets
Specialized BioTherapeutics	$	58,704	$	103,742
Public Health Solutions		70,557		121,290
Corporate		11,173,568		14,054,685
Total	$	11,302,829	$	14,279,717

Note 11. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Years Ended
	December 31,
	2022		2021
Revenues
Specialized BioTherapeutics	$	31,929	$	—
Public Health Solutions		916,982		824,268
Total	$	948,911	$	824,268
(Loss) Income from Operations
Specialized BioTherapeutics	$	(7,614,988)	$	(7,216,450)
Public Health Solutions		26,612		(542,270)
Corporate		(6,650,528)		(5,340,240)
Total	$	(14,238,904)	$	(13,098,960)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	10,087	$	7,804
Public Health Solutions		1,681		1,301
Corporate		12,794		25,056
Total	$	24,562	$	34,161
Other (Expense) Income, Net
Specialized BioTherapeutics	$	102,320	$	135,409
Corporate		(816,690)		(452,164)
Total	$	(714,370)	$	(316,755)
Share-Based Compensation
Specialized BioTherapeutics	$	138,075	$	136,594
Public Health Solutions		4,804		21,884
Corporate		190,510		203,081
Total	$	333,389	$	361,559

	As of December 31,
	2022		2021
Identifiable Assets
Specialized BioTherapeutics	$	103,742	$	128,645
Public Health Solutions		121,290		146,296
Corporate		14,054,685		26,594,986
Total	$	14,279,717	$	26,869,927